Astellas and Poseida enter second research collaboration

2 May 2024
poseida_large

San Diego, USA-based clinical-stage cell and gene therapy company Poseida Therapeutics (Nasdaq: PSTX) saw its shares close up more than 20% at $2.92 yesterday, when it revealed a second collaboration with Japanese drug major Astellas Pharma (TYO: 4503).

Astellas’ wholly-owned Xyphos Bioscience and Poseida have entered into a research collaboration and license agreement to develop novel convertible CAR programs by combining the innovative cell therapy platforms from each of the companies.

The new comes less than a year after Astellas linked up with Poseida to help build out its immuno-oncology pipeline,

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology